DBN1 gene and inhibitor and application thereof

By developing the DBN1 gene and its small molecule inhibitor BTP2, the Hippo signaling pathway is regulated, and the problem of regulating the Hippo signaling pathway in the existing technology is solved, and specific targeted treatment for DBN1-high-expressing tumors is achieved, which enhances the treatment effect and reduces the The impact on normal tissues.

CN119082116APending Publication Date: 2024-12-06SHANGHAI JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411146798.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-08-01
Filing Date
2024-08-20
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively regulate the Hippo signaling pathway, leading to the occurrence and development of tumors, and lacks new regulatory mechanisms and treatment strategies.

Method used

The DBN1 gene and its small molecule inhibitor BTP2 were developed to regulate the Hippo signaling pathway and used in combination with other anti-tumor drugs to enhance therapeutic effects.

Benefits of technology

DBN1 inhibitors can specifically target highly expressed tumor cells, reduce the impact on normal tissues, enhance the therapeutic effect, and reduce dose-dependent side effects. They are suitable for a variety of cancer treatments, especially tumor types with high expression in DBN1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082116A_ABST
    Figure CN119082116A_ABST
Patent Text Reader

Abstract

The invention discloses a DBN1 gene and an inhibitor and application thereof, and relates to the field of biological pharmacy, the nucleotide sequence of the DBN1 gene is shown as SEQ ID NO: 1, the application of the DBN1 gene in regulation and control of a Hippo signal channel, and a small-molecule inhibitor BTP2 aiming at DBN1. The DBN1 inhibitor can specifically aim at DBN1 high-expression tumor cells and can be used as an anti-tumor drug, BTP2 is used as a drug for selectively targeting DBN1 high-expression tumors, growth of the tumors can be effectively inhibited, meanwhile, potential side effects are reduced, and new possibility is provided for treatment of the DBN1 high-expression tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biopharmaceuticals, and in particular to a DBN1 gene and an inhibitor thereof and application thereof. Background Art

[0002] The Hippo signaling pathway is highly conserved and exists from fruit flies to mammals. The core members of this pathway include the serine / threonine kinases MST1 / 2 of the STE20 family, LATS1 / 2 of the NDR kinase family, scaffold proteins MOB1A / B, SAV1, transcription cofactors YAP / TAZ, and downstream transcription factors TEADs. The Hippo signaling pathway exerts its biological functions by regulating the activity of transcription cofactors YAP / TAZ.

[0003] When cells are stimulated by external stimuli and the Hippo signaling pathway is activated, a series of upstream proteins mediate the interaction between MST1 / 2 and SAV1, triggering the autophosphorylation of MST1 / 2. Autophosphorylated MST1 / 2 then phosphorylates the downstream kinase LATS1 / 2. Phosphorylated LATS1 / 2 is activated and forms a kinase complex with MOB1A / B, which then phosphorylates the downstream transcription cofactors YAP / TAZ. Phosphorylated YAP / TAZ is bound by the scaffold protein 14-3-3 and retained in the cytoplasm, then ubiquitinated and degraded through the proteasome pathway. When the Hippo signaling pathway is inactivated, upstream MST1 / 2 and LATS1 / 2 cannot be activated, and unphosphorylated YAP / TAZ enters the nucleus and binds to the transcription factor TEAD1-4, promoting the transcription of downstream genes, thereby promoting cell proliferation and inhibiting apoptosis.

[0004] The activity of YAP / TAZ depends on whether it can aggregate in the nucleus and work with related transcription factors to regulate gene expression. The nuclear aggregation of YAP / TAZ is controlled by a variety of regulatory mechanisms, the most important of which is the phosphorylation of YAP / TAZ by LATS1 / 2 or other kinases. YAP contains five serine sites that can be phosphorylated, of which the S127 site is the most critical. When S127 is phosphorylated by LATS1 / 2, YAP binds to 14-3-3 and is retained in the cytoplasm. In addition, the function of YAP / TAZ is also affected by other post-translational modifications, such as monomethylation of the L494 site can regulate the cytoplasmic retention of YAP, methylation of the K342 site can regulate the continuous activation of YAP in the nucleus, and glycosylation of the S109 site can inhibit the phosphorylation of YAP by LATS1 / 2 and continuously activate YAP. The hardness and shear force of the extracellular matrix (ECM) can also regulate the entry and exit of YAP into the nucleus. When the extracellular matrix is ​​hard and the cytoskeleton tension is high, YAP will enter the nucleus and regulate the expression of downstream genes.

[0005] It is known that abnormalities in the Hippo signaling pathway can lead to the occurrence and development of a variety of tumors. Therefore, whether there are new molecules that regulate the Hippo signaling pathway and whether its abnormalities can lead to the occurrence of tumors, and understanding these regulatory mechanisms are crucial for the development of new treatment strategies.

[0006] Therefore, those skilled in the art are committed to developing a new gene that regulates the Hippo signaling pathway, as well as an inhibitor of the gene and the use of the inhibitor in preparing drugs. Summary of the invention

[0007] In view of the above-mentioned defects of the prior art, the technical problem to be solved by the present invention is to develop a new gene for regulating the Hippo signaling pathway, as well as an inhibitor of the gene and the application of the inhibitor in the preparation of drugs.

[0008] To achieve the above object, the present invention provides a gene, which is the DBN1 gene, and the nucleotide sequence is shown in SEQ ID NO:1.

[0009] The present invention also provides application of DBN1 gene in regulating Hippo signaling pathway.

[0010] The present invention also provides a drug, which is a small molecule inhibitor BTP2 targeting DBN1.

[0011] Furthermore, the drug can be used in combination with other anti-tumor drugs to form a compound preparation.

[0012] Furthermore, other anti-tumor drugs include chemotherapeutic drugs and targeted drugs.

[0013] Further, chemotherapy drugs include alkylating agents, antimetabolites, antitumor antibiotics, antitumor plant and animal component drugs, antitumor hormone drugs, as well as cisplatin, dacarbazine, oxaliplatin, oxaliplatin, coplatin, mitoxantrone and procarbazine.

[0014] Furthermore, alkylating agents include nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide and glyphosate mustard; antimetabolites include deoxyflurane, doxiflurane, fluorouracil, mercaptopurine and methotrexate; antitumor antibiotics include actinomycin D, doxorubicin and daunorubicin; antitumor plant and animal component drugs include vinorelbine, paclitaxel, harringtonine, irinotecan, taxotere and vinblastine; antitumor hormone drugs include atamestane, anastrozole, aminoglutethimide, letrozole, formestane and tamoxifen.

[0015] Furthermore, targeted drugs include RAF / MEK / ERK blockers, EGFR blockers, monoclonal antibodies for specific cell markers, tyrosine kinase receptor inhibitors, anti-tumor angiogenesis drugs, Bcr-Abl tyrosine kinase inhibitors, anti-CD20 monoclonal antibodies, IGFR-1 kinase inhibitors, mTOR kinase inhibitors and ubiquitin-proteasome inhibitors.

[0016] Furthermore, RAF / MEK / ERK blockers include sorafenib and lenvatinib; EGFR blockers include gefitinib and erlotinib; monoclonal antibodies for specific cell markers include cetuximab and anti-HER-2 monoclonal antibodies; tyrosine kinase receptor inhibitors include crizotinib; anti-tumor angiogenesis drugs include bevacizumab, endostatin and bevacizumab; Bcr-Abl tyrosine kinase inhibitors include imatinib and dasatinib; anti-CD20 monoclonal antibodies include rituximab; IGFR-1 kinase inhibitors include NVP-AEW541; mTOR kinase inhibitors include CCI-779; and ubiquitin-proteasome inhibitors include bortezomib.

[0017] Furthermore, the drug can be administered by enteral administration or parenteral administration.

[0018] Furthermore, the combined therapeutic drug combination can be in any of the following forms:

[0019] 1. The DBN1 inhibitor and other anti-tumor drugs are made into separate preparations, the dosage forms of the preparations can be the same or different, and the routes of administration can be the same or different. When used, several drugs can be used simultaneously or sequentially. When administering drugs sequentially, the other drugs should be administered to the body while the first drug is still effective in the body.

[0020] 2. Formulate the DBN1 inhibitor and other anti-tumor drugs into a compound preparation. When the DBN1 inhibitor and other anti-tumor drugs are administered by the same administration route and applied simultaneously, the two can be formulated into a compound preparation.

[0021] 3. The commonly used methods of administration of antibodies are intravenous injection, intravenous drip or arterial infusion. The usage and dosage can refer to the existing technology.

[0022] 4. The common administration methods for small molecule compounds can be gastrointestinal administration or parenteral administration. siRNA, shRNA, and antibodies are generally administered parenterally. It can be administered locally or systemically.

[0023] 5. An effective amount of DBN1 inhibitor and an effective amount of other tumor drugs can be administered synchronously or sequentially. When used, an effective amount of DBN1 inhibitor and an effective amount of other tumor drugs can be used simultaneously, or an effective amount of DBN1 inhibitor and an effective amount of other tumor drugs can be used sequentially. When administering sequentially, the other drug should be applied to the organism while the first drug is still effective for the organism.

[0024] 6. Chemotherapeutic drugs include alkylating agents (such as nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide and glyphosate mustard), antimetabolites (such as nucleotide analogs such as deoxyflurane, doxiflurane, fluorouracil, mercaptopurine, methotrexate), antitumor antibiotics (such as actinomycin D, doxorubicin and daunorubicin), antitumor plant and animal component drugs (such as vinorelbine, paclitaxel, harringtonine, irinotecan, taxotere and vinblastine), antitumor hormone drugs (such as atamestane, anastrozole, aminoglutethimide, letrozole, formestane and tamoxifen), and commonly used chemotherapeutic drugs such as cisplatin, dacarbazine, oxaliplatin, oxaliplatin, coplatin, mitoxantrone and procarbazine.

[0025] 7. Targeted drugs include RAF / MEK / ERK blockers sorafenib and lenvatinib, EGFR blockers such as gefitinib (Gefitinib, Iressa and Iressa) and erlotinib (Erlotinib, Tarceva), monoclonal antibodies for specific cell markers such as cetuximab (Cetuximab, Erbitux) and anti-HER-2 monoclonal antibodies (Herceptin, Trastuzumab, Herceptin), tyrosine kinase receptor inhibitors such as crizotinib (Crizotinib, Xalkori), anti-tumor angiogenesis drugs such as bevacizumab, endostatin and bevacizumab, Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib, anti-CD20 monoclonal antibodies such as rituximab, IGFR-1 kinase inhibitors such as NVP-AEW541, mTOR kinase inhibitors such as CCI-779, ubiquitin-proteasome inhibitors such as bortezomib, etc.

[0026] 8. Other tumor treatment methods may be selected from surgical resection, radiofrequency ablation, argon-helium superconducting surgical treatment, laser ablation treatment, high-intensity focused ultrasound and radiotherapy including one or more of X-knife, R-knife, 3D-CRT and IMRT.

[0027] In preferred embodiment 1 of the present invention, the role and mechanism of DBN1 in liver cancer are described in detail;

[0028] In another preferred embodiment 2 of the present invention, the biological function of DBN1 in liver cancer cells is described in detail;

[0029] In another preferred embodiment 3 of the present invention, the in vivo therapeutic effect of the DBN1 inhibitor BTP2 is described in detail.

[0030] The beneficial technical effects of the present invention are mainly manifested as follows:

[0031] Selective targeting: DBN1 inhibitors can specifically target tumor cells with high DBN1 expression and reduce the impact on normal tissues.

[0032] Synergistic effect: When used in combination with other anti-tumor drugs, it can enhance the therapeutic effect and reduce dose-dependent side effects.

[0033] Wide range of indications: It can be used to treat various types of cancer, especially for tumor types with high expression of DBN1.

[0034] Flexibility in administration: It can be used alone or in combination with other drugs, and the order and route of administration can be flexibly adjusted.

[0035] Specifically, the main functions of the DBN1 gene disclosed in the present invention are as follows:

[0036] 1. Inhibit tumor growth: By reducing the expression level of DBN1 or preventing its function, the proliferation of tumor cells can be slowed down or stopped.

[0037] 2. Enhance chemotherapy sensitivity: Inhibition of DBN1 may increase the sensitivity of tumor cells to chemotherapy drugs.

[0038] 3. Reduce metastasis: Inhibiting DBN1 can reduce tumor metastasis.

[0039] 4. Improve treatment specificity: Treatments targeting DBN1 can act more specifically on tumor cells that overexpress DBN1 and reduce the impact on normal cells.

[0040] 5. Combination therapy: DBN1 targeted therapy can be combined with other therapies (such as chemotherapy, radiotherapy, immunotherapy, etc.) to enhance the overall therapeutic effect.

[0041] The main functions of the DBN1 gene inhibitor BTP2 disclosed in the present invention are as follows:

[0042] 1. Innovative treatment strategy: BTP2 provides a new treatment strategy for DBN1-overexpressing tumors, especially those that are resistant to traditional treatment options.

[0043] 2. Personalized treatment: By testing the patient's DBN1 expression level, more accurate treatment selection can be achieved and the success rate of treatment can be improved.

[0044] 3. Combination therapy potential: BTP2 can be combined with other treatments such as chemotherapy, radiotherapy or immunotherapy to improve the overall treatment effect.

[0045] 4. Improve quality of life: By reducing the impact on normal tissues, BTP2 can help improve patients' quality of life and reduce discomfort during treatment.

[0046] As a drug that selectively targets DBN1-overexpressing tumors, BTP2 can effectively inhibit tumor growth while reducing potential side effects, providing new possibilities for the treatment of DBN1-overexpressing tumors.

[0047] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 It is a schematic diagram of a preferred embodiment 1 of the present invention illustrating that DBN1 is a new key factor regulating YAP activity;

[0049] Figure 2 It is a schematic diagram of a preferred embodiment 1 of the present invention illustrating that DBN1 is closely related to the occurrence and development of liver cancer;

[0050] Figure 3 It is a schematic diagram of a preferred embodiment 1 of the present invention, illustrating that the expression of DBN1 is significantly upregulated in diffuse large B-cell lymphoma, ovarian serous cystadenocarcinoma, pancreatic cancer, testicular cancer, and thymic cancer;

[0051] Figure 4 It is a schematic diagram of a preferred embodiment 1 of the present invention illustrating that DBN1 significantly affects the YAP signaling pathway;

[0052] Figure 5 It is a schematic diagram of a preferred embodiment 2 of the present invention illustrating that DBN1 knockout, knockdown or inhibitor BTP2 can inhibit the proliferation and clone formation of liver cancer cells;

[0053] Figure 6 is a schematic diagram of a preferred embodiment 2 of the present invention illustrating the ability of DBN1 to promote the proliferation of hepatocellular carcinoma cells;

[0054] Figure 7 This is a schematic diagram illustrating a preferred embodiment 2 of the present invention, in which DBN1 knockout significantly inhibits the occurrence and development of liver cancer in a mouse orthotopic liver cancer model;

[0055] Figure 8 It is a schematic diagram of a preferred embodiment 3 of the present invention, illustrating that BTP2 treatment alone or in combination with sorafenib can inhibit the occurrence and development of liver cancer. DETAILED DESCRIPTION

[0056] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.

[0057] Example 1: Role and mechanism of DBN1 in liver cancer

[0058] The purpose of Example 1 is to verify the role of DBN1 in liver cancer and its mechanism of promoting tumor occurrence and development by regulating YAP activity.

[0059] The materials and methods used are as follows:

[0060] - Genome-wide siRNA screening

[0061] - Bioinformatics analysis of liver cancer dataset

[0062] -Sample collection: 60 liver cancer samples and 43 normal liver tissue samples were collected.

[0063] - Immunohistochemical staining: Use specific antibodies for DBN1 and YAP to stain the above samples, and observe and record the results under a microscope.

[0064] -Data analysis: Correlation analysis was performed using appropriate statistical software to assess the correlation between DBN1 and YAP expression.

[0065] -Gene expression analysis: RT-qPCR and Western Blotting were used to detect the expression levels of DBN1 and YAP.

[0066] -siRNA-mediated gene knockdown: Gene knockdown experiments were performed in hepatoma cell lines using siRNA targeting DBN1.

[0067] - Immunofluorescence: Detect the localization of YAP in the cell nucleus.

[0068] -Nuclear-cytoplasmic separation experiment: extract the nucleus and cytoplasm, and detect the distribution of YAP by Western Blotting.

[0069] -Western blotting: Detect the phosphorylation level of YAP and the expression of downstream target genes.

[0070] - Small molecule inhibitor BTP2 (purchased from MedChemExpress, MCE)

[0071] - Treatment with the small molecule inhibitor BTP2: cells were treated with BTP2 to assess its effect on DBN1 function.

[0072] The experimental results are as follows:

[0073] 1. As Figure 1 As shown, genome-wide siRNA screening discovered and identified DBN1 as a new key factor regulating YAP activity; Figure 1 Part A is a schematic diagram of the whole-genome siRNA screening process; Part B is a volcano plot showing the differential regulation of YAP localization after siRNA screening; Part C's gene enrichment analysis shows the signaling pathway associated with YAP localization; Part D shows that DBN1 was identified as the most significant positive regulator among genes related to actin fiber organization.

[0074] 2. Through the analysis of liver cancer datasets, we found that DBN1 is highly expressed in liver cancer tissues, and patients with high DBN1 expression have a shorter survival period.

[0075] In the 60 liver cancer samples and 43 normal liver tissue samples collected, we found through immunohistochemical staining that the expression of DBN1 increased in liver cancer tissues, and at the same time, the expression level of YAP in liver cancer tissues also increased significantly. We conducted a statistical analysis of the results and found that the expression of DBN1 in liver cancer tissues was positively correlated with the expression of YAP.

[0076] Bioinformatics analysis found that the Hippo signaling pathway was significantly enriched in DBN1 in the liver cancer dataset, indicating that DBN1 is a potential oncogene in liver cancer, and the function of DBN1 may be highly correlated with the Hippo signaling pathway transcription cofactor YAP.

[0077] DBN1 is closely related to the occurrence and development of liver cancer. Figure 2 As shown, Figure 2 Parts A and B of the data show that DBN1 is highly expressed in liver cancer and the expression level of DBN1 is negatively correlated with patient survival; Part CE shows that DBN1 is upregulated in liver cancer tissues compared with adjacent adjacent tissues, and the expression level of DBN1 is positively correlated with the expression level of YAP; Part F shows that the Hippo signaling pathway is significantly enriched by DBN1 in the liver cancer dataset.

[0078] 3. Such as Figure 3 As shown, DBN1 expression was significantly upregulated in diffuse large B-cell lymphoma, ovarian serous cystadenocarcinoma, pancreatic cancer, testicular germ cell tumors, and thymoma.

[0079] 4. DBN1 was knocked out in liver cancer cells, and through immunofluorescence and nuclear-cytoplasmic separation experiments, YAP was significantly extranuclear after DBN1 knockout. Figure 4As shown in the figure, the AD part indicates that the entry and exit of YAP into the nucleus is regulated by the phosphorylation of its S127 site. Through immunoblotting detection, it was found that the phosphorylation level of YAP was upregulated and the expression of downstream target genes was inhibited. The EH part of the figure indicates that after overexpression of DBN1, YAP enters the nucleus, the phosphorylation level is downregulated, and the expression of downstream target genes is upregulated.

[0080] Figure 4 The IJ part of the figure indicates that BTP2 can inhibit the function of DBN1 by covalently binding to the K270 / 271 site of DBN1. BTP2 treatment can also inhibit YAP activity and promote YAP nuclear export. BTP2 treatment can also cause YAP nuclear export, confirming that DBN1 is a key regulatory factor for YAP activity. Figure 4 As shown, DBN1 significantly affects the YAP signaling pathway, including Figure 4 The AD part shows that in DBN1-knocked liver cancer cells, YAP significantly exported from the nucleus, its phosphorylation level was significantly upregulated, and its downstream target genes were significantly downregulated at both the protein and mRNA levels; the EH part shows that in DBN1-overexpressed cells, YAP significantly entered the nucleus, its phosphorylation level was downregulated, and its downstream target genes were significantly upregulated at both the protein and mRNA levels; the IJ part shows that treating cells with the DBN1 inhibitor BTP2 promoted YAP export from the nucleus, promoted YAP phosphorylation, and inhibited the expression of downstream target genes.

[0081] Example 2: Biological function of DBN1 in liver cancer cells

[0082] The purpose of Example 2 is to verify the biological functions of DBN1 in liver cancer cells, including proliferation ability and clone formation ability.

[0083] The materials and methods used were:

[0084] -Cell proliferation assay: Use MTT or CCK-8 kit to detect cell proliferation ability.

[0085] -Clonogenic assay: evaluates the ability of cells to form colonies on plates.

[0086] -Subcutaneous transplant tumor model: DBN1 knockdown liver cancer cells were implanted subcutaneously on the back of nude mice and tumor growth was monitored.

[0087] - Mouse in situ liver cancer model: A model of liver cancer induced by inducing MYC overexpression and TP53 knockout through high-pressure tail vein injection of plasmids.

[0088] The experimental results obtained are:

[0089] 1. Knockout or knockdown of the DBN1 gene or treatment with the small molecule inhibitor BTP2 significantly inhibited the proliferation and cloning of liver cancer cells. DBN1 knockout or knockdown or inhibitor BTP2 can inhibit the proliferation and cloning of liver cancer cells. Figure 5 As shown, Figure 5 Parts A and B show that DBN1 knockout, knockdown or inhibitor BTP2 treatment inhibits the proliferation of liver cancer cells; Parts C and D show that DBN1 knockout, knockdown or inhibitor BTP2 treatment significantly inhibits the clone formation of liver cancer cells.

[0090] 2. The effect of DBN1 on tumor cells in vivo was studied by constructing a subcutaneous transplant tumor model. The results showed that the proliferation ability of liver cancer cells knocked out by DBN1 was inhibited in mice, the volume and weight of the tumor were significantly reduced, and the signal of Ki67, a marker of cell proliferation, was weakened. The effect of BTP2 on tumor cells in vivo was detected, and the results were consistent with DBN1 knockout, indicating that inhibiting the activity of DBN1 can inhibit the proliferation of tumor cells in vivo. DBN1 promotes the proliferation of hepatocellular carcinoma cells. Figure 6 As shown, Figure 6 The AD part shows that the growth of xenograft tumors formed after nude mice were transplanted with WT or DBN1-deficient Huh7 cells was slowed down; the EH part shows that the administration of DBN1 inhibitor BTP2 significantly inhibited the proliferation ability of nude mice transplanted with WT or DBN1-deficient Huh7 cells in mice.

[0091] 3. In the mouse orthotopic liver cancer model, MYC overexpression and TP53 knockout were induced by high-pressure tail vein injection of plasmids to induce liver cancer. The results showed that after DBN1 knockout, the occurrence and development of liver cancer slowed down, the liver weight / body weight ratio and the number of liver surface tumors decreased, and liver function was significantly improved. Biochemical analysis results showed that after DBN1 knockout, the protein level of YAP was downregulated, the expression of downstream target genes was weakened, and the signals of Ki67 and YAP, markers of tumor cell proliferation, were weakened. Figure 7 As shown in the mouse orthotopic liver cancer model, DBN1 knockout significantly inhibited the occurrence and development of liver cancer, including Figure 7 Part A is a schematic diagram of the in situ liver cancer modeling and drug treatment in mice; Part BF shows that the liver weight / body weight ratio and the number of liver surface tumors in DBN1 knockout mice were significantly reduced, and the liver function was improved; Part GI shows that after DBN1 knockout, the protein level of YAP and the expression level of downstream target genes in liver tumor cells were significantly downregulated, and the cell proliferation marker Ki67 was reduced.

[0092] Example 3: In vivo therapeutic effect of DBN1 inhibitor BTP2

[0093] The purpose of Example 3 is to evaluate the therapeutic effect of DBN1 inhibitor BTP2 on liver cancer in vivo.

[0094] Materials and methods used:

[0095] - Mouse orthotopic liver cancer model: A liver cancer model was constructed by high-pressure tail vein injection of plasmids overexpressing MYC and knocking out TP53.

[0096] - Drug administration: BTP2 and / or sorafenib were orally administered to mice to evaluate the effects of single or combined administration.

[0097] -Pathological examination: Tumor tissue was obtained for HE staining to evaluate the histological characteristics.

[0098] The experimental results obtained are:

[0099] 1. BTP2 or sorafenib alone can effectively inhibit tumor growth. Sorafenib is a first-line drug for advanced liver cancer, and its mechanism of action is a multi-kinase inhibitor. We established an orthotopic liver cancer model in mice and verified the treatment of tumors by targeting DBN1 by administering the DBN1 inhibitor BTP2. BTP2 or sorafenib alone can effectively inhibit tumor growth in vivo.

[0100] 2. The combined use of BTP2 and sorafenib showed a stronger inhibitory effect.

[0101] 3. The DBN1 inhibitor BTP2 can effectively treat liver cancer when used as a single therapy or in combination with existing chemotherapy drugs. BTP2 treatment alone or in combination with sorafenib can inhibit the occurrence and development of liver cancer. Figure 8 As shown, Figure 5 Parts A and B show that BTP2 alone can inhibit the proliferation and metastasis of liver cancer cells, and the combined use of BTP2 and sorafenib can more significantly inhibit tumor proliferation and metastasis; Parts CD show that in the mouse in situ liver cancer model, the administration of BTP2 or sorafenib alone can inhibit the occurrence and development of liver cancer, and the combined administration of BTP2 and sorafenib has a better inhibitory effect on liver cancer, the liver weight / body weight ratio and the number of liver surface tumors are significantly reduced, and liver function is significantly improved.

[0102] The above examples describe the role and mechanism of DBN1 in liver cancer and its potential as a therapeutic target. These examples not only verify the importance of DBN1 as a key factor, but also demonstrate the effectiveness of DBN1 inhibitor BTP2 in vivo and in vitro, providing a solid foundation for further clinical trials and drug development. Specifically:

[0103] Improved safety: By reducing the impact on normal cells, treatment-related toxic side effects are reduced.

[0104] Performance Indicators

[0105] Efficacy evaluation: In preclinical studies, DBN1 inhibitors were able to significantly slow tumor growth and improve survival rates.

[0106] Safety assessment: It showed good tolerability and low toxicity in animal models.

[0107] Pharmacokinetics: Good absorption, distribution, metabolism, and excretion (ADME) properties ensure the effectiveness and safety of the drug.

[0108] The following production implementations are possible:

[0109] Formulation development: Different preparations can be developed according to different administration routes, such as tablets, capsules, solutions, liposomes, etc.

[0110] Production process: Use existing pharmaceutical technology for large-scale production to ensure stable and reliable product quality.

[0111] Quality Control: Establish a strict quality management system to ensure that products meet international standards.

[0112] Cost-effectiveness: Reduce production costs and improve market competitiveness by optimizing production processes and supply chain management.

[0113] In summary, DBN1 inhibitors and their combined treatments have significant technical advantages and good prospects for industrial application. Through further research and development, they can be transformed into practical treatments to provide patients with more effective treatment options. Therefore, this technology has high translational potential and is worthy of further development and investment.

[0114] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. A gene, characterized in that The gene is the DBN1 gene, and the nucleotide sequence of the DBN1 gene is shown in SEQ ID NO:

1.

2. Use of the gene as claimed in claim 1 in regulating the Hippo signaling pathway.

3. A drug, characterized in that The drug is BTP2, a small molecule inhibitor targeting DBN1.

4. The drug according to claim 3, characterized in that The drug is used in combination with other anti-tumor drugs to form a compound preparation.

5. The drug according to claim 4, characterized in that The other anti-tumor drugs include chemotherapy drugs and targeted drugs.

6. The drug according to claim 5, characterized in that The chemotherapy drugs include alkylating agents, antimetabolites, antitumor antibiotics, antitumor plant and animal component drugs, antitumor hormone drugs, as well as cisplatin, dacarbazine, oxaliplatin, oxaliplatin, coplatin, mitoxantrone and procarbazine.

7. The drug according to claim 6, characterized in that The alkylating agents include nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide and glyphosate mustard; the antimetabolites include deoxyflurane, doxiflurane, fluorouracil, mercaptopurine and methotrexate; the anti-tumor antibiotics include actinomycin D, doxorubicin and daunorubicin; the anti-tumor plant and animal component drugs include vinorelbine, paclitaxel, harringtonine, irinotecan, taxotere and vinblastine; the anti-tumor hormone drugs include atamestane, anastrozole, aminoglutethimide, letrozole, formestane and tamoxifen.

8. The drug according to claim 5, characterized in that The targeted drugs include RAF / MEK / ERK blockers, EGFR blockers, monoclonal antibodies for specific cell markers, tyrosine kinase receptor inhibitors, anti-tumor angiogenesis drugs, Bcr-Abl tyrosine kinase inhibitors, anti-CD20 monoclonal antibodies, IGFR-1 kinase inhibitors, mTOR kinase inhibitors and ubiquitin-proteasome inhibitors.

9. The drug according to claim 8, characterized in that The RAF / MEK / ERK blockers include sorafenib and lenvatinib; the EGFR blockers include gefitinib and erlotinib; the monoclonal antibodies for specific cell markers include cetuximab and anti-HER-2 monoclonal antibodies; the tyrosine kinase receptor inhibitors include crizotinib; the anti-tumor angiogenesis drugs include bevacizumab, endostatin and bevacizumab; the Bcr-Abl tyrosine kinase inhibitors include imatinib and dasatinib; the anti-CD20 monoclonal antibodies include rituximab; the IGFR-1 kinase inhibitors include NVP-AEW541; the mTOR kinase inhibitors include CCI-779; the ubiquitin-proteasome inhibitors include bortezomib.

10. The drug according to any one of claims 3 to 9, characterized in that The drug can be administered enterally or parenterally.